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SIGNIFICANCE
Lentigo maligna is treated to prevent progression to lentigo 
maligna melanoma. The current treatment of choice for len-
tigo maligna is surgical excision. Topical imiquimod is an al-
ternative option. In this study, topical imiquimod treatment 
was successful in 84.2% of patients with lentigo maligna.
Lentigo maligna (LM) is treated to prevent progres-
sion to lentigo maligna melanoma (LMM). Surgery is 
the gold standard, but an alternative treatment is off-
label topical imiquimod. The aim of this study was to 
evaluate the effectiveness of 5% topical imiquimod 
treat ment for lentigo maligna. In the period 2007–
2017 57 patients with lentigo maligna were trea-
ted with off-label topical imiquimod once daily for 12 
weeks. Complete clinical clearance was observed in 48 
patients (84.2%) and partial clearance in 3 patients 
(5.3%). Three patients (5.3%) showed no response 
and another 3 patients (5.3%) stopped treatment due 
to side-effects. After 4.5 years, during follow-up, one 
patient developed a lentigo maligna melanoma, which 
was subsequently excised. Treatment with topical 
imiquimod resulted in complete clearance of lentigo 
maligna in 48 out of 57 patients (84.2%). Topical imi-
quimod is an acceptable treatment option for patients 
with lentigo maligna who prefer topical treatment to 
surgery or radiotherapy.
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Lentigo maligna (LM) is considered a type of me-lanoma in situ. It is prevalent in a predominantly 
elderly population with a fair skin type. LM typically 
occurs on chronic sun-exposed skin, such as the head 
and neck area, where critical anatomical structures are 
located. Elderly patients often have multiple comorbi-
dities and, as a consequence, clinical management may 
be challenging. Several studies have shown an increased 
incidence of LM over recent decades (0.54 LM/100,000 
patient years to 1.99 LM/100,000 patient years) (1–4). 
Treatment of LM is recommended in order to prevent 
progression to lentigo maligna melanoma (LMM), which 
can metastasize. The true progression rate is unknown, 
but a recent epidemiological study describing 10,545 LM 
and 124 LMM patients reported that the cumulative risk 
of LMM developing after a LM on any location after 25 
years is 2.0–2.6%. The progression of individual lesions 
could not be evaluated in this study (1). 
According to the current European Consensus Gui-
deline (5), surgical excision is the gold standard for 
treatment of LM. Alternative treatment options, such as 
off-label topical imiquimod 5%, radiotherapy, or watch-
ful waiting, are mentioned in the guideline, but there is 
no recommendation on their application (5). Surgical 
excision of larger lesions can result in disfiguring scars 
or functional impairment, and radiotherapy could poten-
tially cause secondary malignancies or radiodermatitis 
(6, 7). Off-label topical imiquimod has the advantage of 
providing a good cosmetic outcome and it is easy to use 
for elderly patients (8). 
The reported response rate to off-label topical imiqui-
mod for LM varies between 37.0% and 78.6% (9–12). 
This wide range of response rates could be due to the 
use of different treatment regimens.
A survey performed by our group among 415 derma-
tologists in Europe showed that non-surgical options are 
used quite often. Of the respondents, 17.0% indicated 
that they use radiotherapy, 30.6% topical imiquimod, 
and 19.6% watchful waiting when treating LM patients 
>70 years of age (13).
Patients with LM have been treated with off-label 
topical imiquimod 5% since 2007. The patients recrui-
ted for this cohort between 2007 and 2012 have been 
described previously by Kirtschig et al. (8), who treated 
27 patients with topical imiquimod, of whom 20 (74%) 
showed complete clinical and histological clearance 
with a mean follow-up of 39 months. The current study 
expands this cohort with 30 additional patients with LM 
treated between 2012 and 2017. 
The aim of this study was to analyse all patients 
with LM treated prospectively with off-label topical 
imiquimod at our centre between November 2007 and 
December 2017, in order to evaluate the effectiveness 
of this treatment. Data were collected retrospectively by 
reviewing clinical records.
METHODS
Patients were usually referred to our academic referral centre 
when they were not eligible for surgical treatment or did not want 
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surgical treatment. Often these patients were referred specifically 
for treatment with off-label topical imiquimod. All patients were 
informed about the advantages and disadvantages of excision, 
radiotherapy, off-label topical imiquimod, and watchful waiting. 
A shared decision for treatment was made depending on the lo-
cation of the lesion, comorbidity of the patient, feasibility of the 
treatment option, and the patient’s preference. If off-label topical 
imiquimod was chosen, informed consent was obtained prior to 
treatment. If watchful waiting was chosen, patients were offered 
check-up appointments for clinical revision every 3 months. When 
clinical or dermoscopic changes were seen during these check-up 
appointments, the treatment options were discussed again. 
Patients were instructed to apply topical imiquimod to the 
lesion daily with a 1–2-cm margin for a total of 12 weeks. The 
aim was to achieve at least 10 weeks of inflammation. Patients 
had a check-up appointment every 4 weeks. Depending on the 
inflammatory reaction, the treatment schedule was adapted. If the 
inflammation was “too intense” (erythema and erosion of the skin 
was seen outside the application area), patients were instructed to 
apply imiquimod 3 times a week, and if the inflammatory response 
was “too mild” (no erythema or erosions of the skin were seen) 
patients were instructed to apply imiquimod twice daily (8, 14). 
The treatment protocol for off-label topical imiquimod for LM 
was reviewed and consented by the ethics committee of Vrije 
Universiteit Medical Center.
Some patients had received other treatment prior to topical imi-
quimod, by excision, cryotherapy, or radiotherapy. Such lesions 
were regarded as recurrent. Previous biopsies taken elsewhere 
were sent to the pathology department for revision by an ex-
perienced dermatopathologist, to confirm the diagnosis of LM. 
All samples were examined using haematoxylin and eosin and 
Melan-A (MART-1) staining. LM was histologically defined as 
a proliferation of atypical melanocytes along the basal cell layer 
of the epidermis, with possible extension into hair follicles and 
ascension of melanocytes. Post-inflammatory hyperpigmentation 
(PIH) was defined by the presence of melanophages in the dermis 
without proliferation of atypical melanocytes (15). 
After treatment, if no residual pigmentation was visible with 
the naked eye or by dermoscopy a lesion was deemed comple-
tely clinically clear. Lesions were classified as partially clear 
if pigmentation was reduced in comparison with pre-treatment 
photographs, but still visible macroscopically or by dermoscopy. 
When a lesion did not change at all, the patient was classified 
as a non-responder. 
After completion of treatment, patients were invited for a check-
up visit every 6 months. Clinical assessment included comparison 
with previous dermoscopic and photographic documentation. 
During follow-up, if a patient showed pigmentation at the treated 
site at any time, a 3-mm punch biopsy was performed to investigate 
whether the pigmentation was PIH or residual LM.
A sub-analysis of our cohort was performed to determine 
whether there was a difference between a total of ≤ 60 applications 
or > 60 applications. 
Statistical analysis
Data were analysed using descriptive statistics with SPSS (version 
22.0; IBM Co. χ2 tests were used for sub-analysis of the difference 
between ≤ 60 applications and > 60 applications in total. 
RESULTS
A total of 57 patients with histologically proven LM were 
treated with topical imiquimod between 2007 and 2017. 
Of the 57 treated patients, 24 were men (42.1%) and 33 
were women (57.9%), with a mean ± standard deviation 
(SD) age of 76 ± 10.6 years. There was a median (inter-
quartile range; IQR) follow-up of 36 (24–60) months. 
Most lesions were located on the nose (n = 23) or cheek 
(n = 20), some on the forehead (n = 8), the temple (n = 3), 
the chin (n = 1), the cutaneous upper lip (n = 1) and the 
earlobe (n = 1) (Fig. 1). The lesions had a median (IQR) 
longest diameter of 15 mm (10–23 mm). Of the 57 
patients, 46 had primary lesions (80.8%) and 11 had re-
current lesions (19.2%). The patients with recurrent LM 
were treated surgically (n = 5), by cryotherapy (n = 5) or 
by an unknown modality (n = 1) prior to treatment with 
topical imiquimod. 
The median (IQR) number of applications of topical 
imiquimod was 84 in total (77–84 applications). Of the 
Fig. 1. Overview of patients with 
lentigo maligna (LM) treated with 
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57 patients, 10 (17.5%) applied imiquimod ≤ 60 times 
in total. The remaining 47 patients (82.5%) applied imi-
quimod > 60 times in total (Table I).
Clinical clearance, histopathological clearance and 
retreatment
Complete clinical clearance was found in 48 patients 
(84.2%). Of these patients, 29 underwent a post-treatment 
3-mm punch biopsy. All of these biopsies showed PIH 
and histological clearance of LM. The other 19 patients 
declined a post-treatment biopsy. They returned for 
follow-up after treatment. 
Partial clinical clearance was found in 6 patients 
(10.5%). One patient underwent re-excision of the LM 
lesion without a post-treatment biopsy. Histopathological 
examination confirmed the presence of residual LM. The 
remaining 5 patients had a 3-mm punch biopsy performed 
after treatment. Of these 5 biopsies, 3 showed PIH with-
out residual LM, the 2 other biopsies showed residual 
LM. The 3 patients with a clear biopsy were added to the 
total of patients with complete clinical clearance. The 2 
patients with a biopsy showing residual LM underwent 
surgical excision. 
Three patients (5.3%) did not respond to treatment. Of 
these, 2 underwent a biopsy, which showed residual LM 
in both cases. Both patients declined surgical excision 
or radiotherapy and opted for watchful waiting. These 
patients were reviewed clinically every 3 months; so far 
they have not been re-treated. The third non-responder 
underwent surgical excision.
Another 3 (5.3%) patients stopped treatment early 
due to side-effects. Side-effects observed in this study 
included flu-like symptoms (n = 11), lymphoedema of the 
cheek (n = 3), headache (n = 7) and a sterile conjunctivitis 
(n = 3). The 3 patients who discontinued treatment due 
to side-effects did not undergo biopsies post-treatment. 
Residual pigmentation was still visible in these patients. 
One patient was retreated by excision and referred back 
to his original dermatologist. The 2 other patients were 
reviewed clinically every 3 months and have not been 
re-treated so far (Fig. 1).
Recurrence after off-label 5% topical imiquimod
A total of 6 LM recurred (10.5%) after a mean follow-
up period of 22.5 months (5–55 months). Recurrences 
after treatment with topical imiquimod were found on 
the chin (n = 1), forehead (n = 2), cutaneous upper lip 
(n = 1), cheek (n = 1) and earlobe (n = 1). In 2 of 6 patients, 
recurrences were found after 5 months. Both patients had 
recurrent LM following surgery or cryotherapy, prior to 
treatment with topical imiquimod. In the other 4 patients 
recurrences were seen after 10, 29, 31 and 55 months. 
The patient who showed recurrence after 55 months 
initially presented a histologically proven, primary LM 
on her left earlobe. After treatment a biopsy showed 
no residual LM, and check-ups were performed every 
6 months. No recurrence was seen, but after 4.5 years 
she reported repigmentation at the treated site. A biopsy 
showed LMM (Breslow thickness 0.4 mm, T1aN0M0), 
which was subsequently surgically excised. This patient 
was checked regularly for 2 years after excision and, 
to date, she has not developed local recurrence or me-
tastasis. All 6 patients with recurrent LM were offered 
alternative treatment; 4 patients opted for excision and 
2 for radiotherapy (Table II). 
Subanalysis
A subanalysis showed no significant difference in 
complete clinical clearance rates between patients who 
applied imiquimod ≤ 60 or > 60 times in total (p = 0.24, 
data not shown). 
DISCUSSION
Our academic outpatient clinic treated 57 patients with 
LM with off-label topical imiquimod (one application 
Table I. Demographics of patients with lentigo maligna (LM) (n = 57) 
treated with off-label 5% topical imiquimod
Characteristics
Men/women, n (%) 24 (42.1)/33 (57.9)
Age, years, mean ± SD 76 ± 10.6
Follow-up, months, median (IQR) 36 (IQR 24–60) 
Primary/recurrent, n (%) 46 (80.8)/11 (19.8)
Longest length of LM, mm, median (IQR) 15 (10–23) 
Location, n (%)
  Nose 23 (40.4) 
  Cheek 20 (35.1)
  Forehead 8 (14.0)
  Temporal 3 (5.4)
  Chin 1 (1.7)
  Cutaneous lip 1 (1.7)
  Earlobe 1 (1.7)
Total applications of imiquimod, median (IQR) 84 (77–84) 
Patients who applied imiquimod <60 times, n (%) 10 (17.5)
Patients who applied imiquimod >60 times, n (%) 47 (82.5)
SD: standard deviation; IQR: interquartile range.
Table II. Recurrence of lentigo maligna (LM) after treatment with off-label 5% topical imiquimod
Case number Primary or recurrent Previous treatment Location Time to recurrence (months) Treatment after recurrence
Case 1 Recurrent Cryotherapy Cheek   5 Excision
Case 2 Recurrent Excision Upper lip   5 Excision
Case 3 Primary – Forehead 10 Radiotherapy
Case 4 Primary – Forehead 29 Excision
Case 5 Primary – Chin 31 Radiotherapy
Case 6 Primary – Earlobe 55 (progression to LMM) Excision
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daily for 12 weeks) over a 10-year period. This treat-
ment resulted in complete clinical clearance in 84.2% of 
patients, with a 10.5% recurrence rate during follow-up. 
One patient (1.8%) treated with topical imiquimod sho-
wed progression to LMM after 4.5 years of follow-up. 
The progression rate of LM to LMM in this study was 
1.8%, which is similar to previous studies on topical 
imiquimod for LM. A systematic review of LM treated 
with topical imiquimod described 471 treated patients, 
with only 9 cases progressing to LMM following topical 
imiquimod (1.9%) (11).
Kai et al. (12) reported a clearance rate of 62.5% 
(n = 40). The patients in this study applied topical 
imiquimod 3 times a week for 6 weeks, followed by 
5 times a week for 4 weeks, for a total of 38 applica-
tions. Another study by Marsden et al. (9) reported a 
37% (n = 27) histological clearance rate. These patients 
applied topical imiquimod 5 times a week for 12 weeks; 
a total of 60 applications. The more intense treatment 
regimen used in the current study could explain the 
higher clearance rate observed. This is concurrent with 
the results of a systematic review, which has shown that 
the odds ratio of achieving complete clinical clearance 
is 8 times higher if topical imiquimod is applied > 60 
times in total (10, 11). 
Compared with staged surgical techniques or ra-
diotherapy, topical imiquimod has a higher recurrence 
rate, at 10.5%. Surgical excision with a 5-mm margin 
has a recurrence rate of 30% after 5.5 years (16) while 
staged excision techniques, such as Mohs micrographic 
surgery or the “spaghetti technique” show a superior 
recurrence rate of 4–5.9% (1, 17, 18). Radiotherapy has 
a reported recurrence rate of 5% after 3 years (19). To-
pical imiquimod, however, has the advantages of being 
non-invasive, providing a good cosmetic outcome, and 
being easy to use for elderly patients. To our knowledge, 
no comparative studies between treatments have been 
published to date. 
To determine the position of topical imiquimod in a 
treatment algorithm it is necessary to define the primary 
goal of treatment. Currently, the main treatment goal 
for LM is to prevent progression to LMM. The true 
progression rate is unknown, although Greveling et al. 
reported that the cumulative risk of developing LMM 
after primary LM is 2–2.6% over a course of 25 years 
(1). Patients with LM are mostly elderly and have been 
shown to have a relative survival rate of 104% compared 
with the general population, while patients with LMM 
have a relative survival rate of 99% after treatment (1). 
In contrast, studies on malignant melanoma (non-LMM) 
showed a relative 5-year survival of 76–83.4% after 
treatment (20, 21). The current study found no LM- or 
LMM-related deaths. A previous study on surgical treat-
ment of LM and LMM by Gambichler et al. (22) reported 
similar findings. In a cohort of 270 patients (124 with LM 
and 146 with LMM) who were treated surgically they 
observed no LM- or LMM-related deaths after a mean 
follow-up of 55 months. 
Swetter et al. (23), have suggested that histological 
clearance should not necessarily be the gold standard to 
measure the success of LM treatment. In general, LM 
develops on actinically damaged skin. In sun-damaged 
skin, morphologically atypical, but biologically non-ma-
lignant, melanocytes may reside at the dermal–epidermal 
junction and may simulate LM. This makes diagnosis dif-
ficult. Histologically these atypical, but non-malignant, 
melanocytes are indistinguishable from true malignant 
cells, even with the use of immunostains (MART1/
melan-A, SOX10, MiTF and soluble adenylyl cyclase) 
(23, 24). Thus it is difficult to prove radical excision and, 
subsequently, striving for histological clearance could 
lead to large, perhaps unnecessary, defects. 
The current study has several limitations. Firstly, 
patients referred to us for LM are usually elderly, who 
often do not want to undergo surgical excision. Most of 
these patients did not want radiotherapy either, because 
it requires daily travelling to the hospital for several 
weeks. Therefore, this patient population is prone to 
selection bias, which may have influenced the study 
results. Secondly, 11 of our patients had been diagno-
sed with recurrent LM prior to treatment with topical 
imiquimod. This may have confounded the response to 
therapy. Lastly, the usage of single 3-mm punch biop-
sies for histopathological examination may have led to 
sampling error in cases of large LMx. 
Based on these results, we conclude that off-label 
topical imiquimod is an acceptable treatment option for 
patients with large LM lesions and for those who do not 
want surgical excision or radiotherapy. Future studies 
should focus on comparing treatment options for LM, 
and whether histological clearance should be regarded 
as the most important measure of outcome.
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